Kotra's is merely traded at PER 12.5x whereas Ahealth, Dpharma, Yspsah and Nova are all fetched PER between 17x and 22x. Time to catch up with the valuation
Monopoly over the local pharmaceutical business. There is not a single company listed on Bursa that has their in-house manufacturing line and brands. Give me one company except Pharmaniaga that actually deals with production. None
Thanks zzprozaz. Surged in profit margin is highly likely due to increasing in appeton products sales. Nova is another one enjoying high profit margin from its supplement products.
Lol already up so much then start to write so long to promote. IR department provides useless information unless you work as buy-side analysts from large funds. I got ignored by IR because I worked at a smaller fund and I was covering a large cap.
IR's job is to make presentation decks and help analysts prepare models. Their information can be found anywhere. Surge in profit margins has been priced in. The time to buy was Q3 2021
Kotra has invested RM 179m in PPE from FY2010 to FY2021 and the accumulated depreciation is about RM 124m during this period. With the PPE depreciation in RM 14m per annum and nil massive Capex, the depreciation amount will be reduced RM 3m/year after 3 years.
Kotra needs to prove to the market that its margin hike is sustainable for 4 continuous quarters . Therefore, the upcoming QR is crucial justify the margin leap.
Appeton sales in Jan to March should be good as higher covid cases in this period, recent 2 quarters result mainly support by higher local sales mainly contribute by Appeton in the covid period
Not many interested in tiny traded company la. Difficult to make money in short term. Hidden hands are drawing the graph judging from the trades in the past few weeks.
Like you said, mid term traders are not interested in Kotra because this stock won't move. Pharmaceuticals perform good in recessions. Kotra Industries is similar to JNJ but a microcap biotech/healthcare stock
treasurehunt, but Kotra capacity utilisation only 40% or 50%, still got many capacity to grow oversea market… I think it was not due to not enough capacity….
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Posted by treasurehunt > 2022-02-24 20:19 | Report Abuse
You sold today ke? Lolz